

NEWS RELEASE

HYDERABAD, INDIA (17 August' 2020) -- Suven Pharmaceuticals Limited ("SPL", "Company") today announced unaudited financial results for the quarter ended 30 June 2020. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 17 August' 2020 at Hyderabad.

CONDENCED STATEMENT OF OPERATIONS

All figures in INR Million, except EPS

	Stand Alone - 3 Months ended			Consolidated - 3 Months ended		
	Q1 Jun 20	Q4 Mar 20	Q1 Jun 19	Q1 Jun 20	Q4 Mar 20	Q1 Jun 19
Revenue	2,439.72	1,901.05	1,998.36	2,439.72	1,901.05	1,998.36
Operational expenses	1,261.25	1,074.97	949.23	1,261.51	1,075.11	949.33
Depreciation and Amortisation	70.63	69.64	54.97	70.63	69.64	54.97
Finance cost	32.06	72.04	34.42	32.06	72.18	38.19
Total expenses	1,363.95	1,216.65	1,038.63	1,364.21	1,216.92	1,042.50
Tax	263.47	151.99	210.48	263.47	151.99	210.48
Share of Profit/(Loss) of Associate				103.18	209.69	173.66
Profit After Tax for the period/year	812.30	532.41	749.25	915.22	741.82	919.04
Other comprehensive income	(2.05)	(1.39)	(0.28)	(2.05)	(1.39)	(0.28)
Total comprehensive income	810.26	531.02	748.98	913.17	740.44	918.77
Paid up equity capital	127.28	127.28	127.28	127.28	127.28	127.28
Earnings per share of Rs.1 each (EPS)	6.38	4.18	5.89	7.19	5.83	7.22

On consolidation of the accounts of Suven Pharma, Inc., USA, wholly owned subsidiary, the PAT includes unrealised share of profit in Rising Pharma Holdings, Inc., USA an associate company.

1. The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).
2. The Board of Directors considered and recommended the issue of bonus shares in the ratio of 1:1, subject to approval of the members in the ensuing annual general meeting.
3. The Board announced Employee Stock Option Plan (ESOP) 2020, subject to approval of members in the ensuing annual general meeting of the company.
4. Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other contents in buildings were damaged. The company has lodged an initial estimate of loss with insurance company and survey is currently ongoing. During the quarter ended June 30, 2020, the company has written off net book value of assets aggregating Rs.109.30 Lakhs and recognized a minimum insurance claim receivable for equivalent amount.
5. On 30 Jan 2020, the World Health Organization (WHO) declared the coronavirus (COVID-19) outbreak a "Public Health Emergency of International Concern" and on 11 Mar 2020, declared it to be pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, quarantines in certain areas and forced closure for certain types of public places and businesses. The actions taken to mitigate the spread expected to continue for more time and may have adverse impact on economics in different geographies in which your Company operates. It is unknown for how long the adverse conditions associated with COVID-19 will last. To date, the Company has not experienced any major consequences or loss of business, which will materially impact the financial conditions of the Company.

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited